康恩貝(600572.SH):甲鈷胺片通過仿製藥質量和療效一致性評價
格隆匯8月2日丨康恩貝(600572.SH)公佈,近日,公司全資子公司杭州康恩貝制藥有限公司(“杭州康恩貝”)收到國家藥品監督管理局(“國家藥監局”)核准簽發的《藥品補充申請批准通知書》,杭州康恩貝生產的甲鈷胺片通過仿製藥質量和療效一致性評價。
甲鈷胺片主要用於治療周圍神經病。周圍神經病是指周圍運動、感覺及自主神經的結構和功能障礙所致的一類疾病,常見周圍神經病損有三叉神經痛、面神經炎、面肌痙攣、舌咽神經痛、枕神經痛,以及坐骨神經痛、肋間神經痛、多發性周圍神經病等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.